Literature DB >> 18471768

Minimising moxifloxacin resistance with tuberculosis.

Karl Drlica, Xilin Zhao, Barry Kreiswirth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18471768     DOI： 10.1016/S1473-3099(08)70077-X

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  4 in total

Review 1.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

2.  A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.

Authors:  John Gar Yan Chan; Anneliese S Tyne; Angel Pang; Hak-Kim Chan; Paul M Young; Warwick J Britton; Colin C Duke; Daniela Traini
Journal:  Pharm Res       Date:  2013-11-16       Impact factor: 4.200

3.  In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.

Authors:  Areeya Disratthakit; Norio Doi
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

4.  In vitro model of mycobacterial growth arrest using nitric oxide with limited air.

Authors:  Syed Hussain; Muhammad Malik; Lanbo Shi; Maria Laura Gennaro; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.